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Background/aim: This study aimed to compare the levonorgestrel intrauterine system (LNG-IUS) with abdominal hysterectomy (TAH)
and total laparoscopic hysterectomy (TLH) as first-line treatments for heavy menstrual bleeding (HMB).
Materials and methods: Ninety-eight patients aged 20–55 years who complained of regular heavy menstrual bleeding were enrolled in
the study. The TAH group included 29 patients, the LNG-IUS group included 34, and the TLH group included 35. These groups were
compared in terms of quality of life and the cost-effectiveness of the selected methods. Quality of life was assessed using the 36-Item
Short Form (SF-36), and cost-effectiveness was assessed according to the current cost of each approach.
Results: The quality of life parameters, with the exception of mental health, improved significantly in the LNG-IUS, TAH, and TLH
groups. The mean costs of the LNG-IUS, TAH, and TLH procedures were $99.15 ± 4.90, $538.82 ± 193.00 and $1617.05 ± 258.44,
respectively (P < 0.05). Overall, LNG-IUS was the most cost-effective treatment option.
Conclusion: The outcome measures of the SF-36 revealed that after 6 months, these treatments were equal in terms of quality of life,
except for mental health. LNG-IUS was the most cost-effective approach.
Key words: Cost analysis, levonorgestrel-releasing intrauterine system, menorrhagia, surgery, quality of life

1. Introduction
Heavy menstrual bleeding (HMB) is a widespread
gynecological problem that accounts for more than 10%
of outpatient referrals to gynecological outpatient clinics
(1). HMB can be defined as blood loss that exceeds 80
mL per menstrual cycle (2). HMB may result in sexual
dysfunction and psychological morbidity that further
affects quality of life and working capacity (3). Although
hysterectomy is the last, but definitive, treatment option
for HMB, its associated morbidity and complication
rate exceed those of other treatment modalities (4), and
the high cost of a surgical procedure should always be
considered. The levonorgestrel intrauterine system (LNGIUS) is an effective treatment for HMB (5). Women using
the LNG-IUS may stay in the hospital for shorter times and
typically are less affected in terms of working capacity. The
LNG-IUS is a cost-effective alternative to hysterectomy for
the treatment of this disorder (6). The aim of this study
is to evaluate the quality of life and cost-effectiveness of
* Correspondence: cevdetadiguzel@yahoo.com

the LNG-IUS compared to total abdominal hysterectomy
(TAH) and total laparoscopic hysterectomy (TLH).
2. Materials and methods
The study was performed at the Department of Obstetrics
and Gynecology, Adana Numune Education and Research
Hospital, Adana, Turkey. A total of 104 patients aged 20–55
years, with complaints of regular HMB, were enrolled in the
study from January 2013 to June 2015. Ninety-eight women
completed the study. The inclusion criteria were the presence
of HMB, reproductive age, a completed family, failure of
appropriate first-line oral medical therapy, normal Pap smear,
no pelvic pathology on ultrasound, normal endometrial
biopsy, and pictorial blood loss assessment chart scores of
≥100 (average of two consecutive cycles). The exclusion
criteria were previous endometrial resection/ablation, any
uterine pathology on scans or hysteroscopy, incompletely
investigated abnormal uterine bleeding, and postmenopausal
bleeding. The local ethics committee approved this study.
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A total of 104 women with HMB, who were
unresponsive to medical treatment, were informed about
their treatment options. Three treatment options were
offered to these patients: TAH, TLH, and LNG-IUS. The
patients were assigned to three groups according to their
treatment choices. The first group consisted of 32 patients
who received TAH treatment, the second group included
37 patients who were treated with TLH, and the third
group included 35 patients treated with the LNG-IUS.
Written informed consent was obtained from each patient.
Three patients in the TAH group, one patient in the LNGIUS group, and two patients in the TLH group were lost
to follow-up (Figure 1). All procedures were performed
using the same techniques by the same surgeons. Standard
preoperative assessments were performed together
with pelvic and abdominal examinations, abdominal
and transvaginal ultrasound examinations, Pap smears,

Figure 1. Study design.
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and endometrial biopsies to exclude any pathologies.
Intraoperative prophylactic antibiotic therapy with
cefazolin was administered to the TAH and TLH groups.
The patients were discharged from the hospital when they
could tolerate a normal diet, were able to dress themselves,
and were fully mobile.
The LNG-IUS (Mirena, Schering Oy, Finland) was
inserted into the uterine cavity within 7 days of the onset
of menstruation. It was loaded into the insertion tube,
and after the operator had secured the threads, set the
flange, and released the arms, the device was advanced
into the uterine fundus and was released, followed by the
withdrawal of the inserter.
For the TLH surgeries, the patients were appropriately
placed in the lithotomy position. The uterine
manipulator was placed before the surgical intervention.
An intraumbilical incision was used to induce
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pneumoperitoneum. A trocar of 10–12 mm was placed
at the umbilicus. Two additional 5-mm satellite trocars
were placed in each ilioinguinal area, and a third satellite
trocar was placed in the left-upper quadrant as necessary.
The uteroovarian and round ligaments were sealed using
bipolar electrosurgery. Next, a bladder flap was created.
After the bladder flap had been created in the anterior
region, the uterine arteries were sealed and cut at the sides
at the internal cervical os level. Anterior and posterior
culdotomies were performed using monopolar cautery.
The uterus was removed and the vaginal cuff was closed.
For the TAH surgeries, following a transverse incision,
the peritoneal cavity was entered. The uteroovarian and
round ligaments were clamped, cut, and ligated bilaterally.
The perivesical space was dissected to separate the bladder.
Sharp dissection was used to skeletonize the uterine
vessels, which were clamped, cut, and ligated bilaterally.
The cervicovaginal junction at the level of the external
cervical os was palpated, and an incision was made to
enter the vaginal apex. A circumferential vaginal incision
was made to amputate the cervix and uterus. The vaginal
cuff was closed.
The primary outcome of the trial consisted of a
comparison of the patients’ quality of life prior to the
treatment and 6 months after the completion of the three
treatment procedures. Quality of life was measured with
the 36-Item Short Form (SF-36). The SF-36 is a 36-item,
self-administered questionnaire that yields scores for
the following eight domains of life: physical functioning,
role limitations-physical, role limitations-emotional,
bodily pain, general health perceptions, vitality, social
functioning, and mental health. Each of the domains
is scored on a 100-point scale on which higher scores
indicate better functioning.

The secondary outcome of the trial consisted of
the comparison of the cost-effectiveness of each of the
three treatment procedures. The costs, including the
use of hospital services (i.e. operations, inpatient days,
procedures, and outpatient visits) and medication, were
obtained from the medical records.
2.1. Statistical analysis
The statistical analyses were performed using SPSS 13.0
for Windows. Descriptive statistics were calculated for all
variables. The data are reported as mean ± SD or median
(minimum and maximum), as appropriate. To compare the
means between the two groups for normally distributed
data, t-tests and paired t-tests were performed. One-way
ANOVA was performed to compare the means among the
three groups for normally distributed data. P < 0.05 was
accepted as the prespecified level of statistical significance.
3. Results
This study included 98 women between 20 and 55 years
of age. During the study, 34 women were treated with
the LNG-IUS, 29 women were treated with TAH, and
35 women were treated with TLH for HMB. In the three
groups, all patients completed the 6-month follow-up.
The sociodemographic and obstetric characteristics of the
women in the study are illustrated in Table 1. The mean
ages of the women in the LNG-IUS, TAH, and TLH groups
were 41.32 ± 5.76, 48.37 ± 4.42, and 45.55 ± 5.20 years,
respectively. The mean body mass indices (BMIs) in the
LNG-IUS, TAH, and TLH groups were 27.43 ± 4.67, 30.47
± 5.23, and 31.21 ± 4.38, respectively. The mean parities of
the women in the LNG-IUS, TAH, and TLH groups were
2.85 ± 1.50, 3.82 ± 1.96, and 3.94 ± 1.82, respectively. There
were significant differences in the sociodemographic and
obstetric characteristics among the three groups. These
differences were due to the LNG-IUS group. A comparison

Table 1. Sociodemographic and obstetric characteristics of the patients.
TAH
Group 1

TLH
Group 2

LNG-IUS*
Group 3

P

Age

48.37 ± 4.42

45.55 ± 5.20

41.32 ± 5.76

0.000

BMI

30.47 ± 5.23

31.21 ± 4.38

27.43 ± 4.67

0.003

Parity

3.82 ± 1.96

3.94 ± 1.82

2.85 ± 1.50

0.004

Educational background
Illiterate
Grade school
High school
University

11 (47.8%)
15 (25.5%)
4 (30.8%)
0 (0.0%)

9 (39.1%)
23 (41.8%)
2 (15.4%)
1 (14.3%)

3 (13%)
18 (32.7%)
7 (53.8%)
6 (85.7%)

0.001

*Statistically significant P-values were found to be caused by the LNG-IUS group following an analysis of the results by
Bonferroni post hoc test.
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of the educational backgrounds of the three groups is
displayed in Table 1. There was a significant difference in
educational backgrounds among the three groups (P =
0.001).
The SF-36 scores in each of the three groups indicated
favorable developments (Table 2). Compared to the
baseline values, the 6-month follow-up results indicated
improvements in the general health, physical function,
physical role, emotional role, social function, vitality,
and pain parameters in all three groups. There were
significant improvements in these parameters in the three
groups. However, significantly greater improvements were
observed in the parameters of physical function, physical

role, and emotional role in all groups; general health
in the TAH and TLH groups; and social function and
vitality in the TLH and LNG-IUS groups (P < 0.05). Only
the mental health parameters failed to exhibit significant
improvements in any group at 6 months (P > 0.05).
In the present study, no complications were observed
after the TAH or TLH surgeries. One uterine perforation
was observed in the LNG-IUS group, and the device was
removed laparoscopically. One woman did not benefit
from the LNG-IUS after 6 months of follow-up and
eventually underwent a hysterectomy.
The analysis of the cost-effectiveness of the treatments
is displayed in Figure 2. The mean costs of the LNG-IUS,

Table 2. Quality of life assessments based on the SF-36 measures.
TAH
Group 1

TLH
Group 2

LNG-IUS
Group 3

Preop

Postop

P

Preop

Postop

P

Preop

Postop

P

General health

41.55 ± 15.92

55.17 ± 16.00

0.000

46.42 ± 16.91

58.28 ± 15.76

0.000

53.38 ± 24.51

62.05 ± 20.04

0.030

Physical function

53.44 ± 25.25

77.41 ± 20.38

0.000

49.57 ± 21.53

79.85 ± 15.69

0.000

51.61 ± 31.37

86.47 ± 15.78

0.000

Physical role

21.55 ± 33.88

67.24 ± 34.78

0.000

16.42 ± 27.07

75.00 ± 30.31

0.000

27.20 ± 40.06

77.94 ± 32.42

0.000

Emotional role

27.58 ± 38.90

67.81 ± 30.18

0.000

18.09 ± 28.40

75.23 ± 32.68

0.000

40.19 ± 46.98

73.52 ± 38.29

0.000

Mental health

54.20 ± 20.18

60.13 ± 13.33

0.213

55.76 ± 15.34

56.58 ± 13.47

0.816

63.29 ± 19.03

66.23 ± 14.81

0.374

Social function

57.76 ± 28.62

67.67 ± 22.29

0.078

42.50 ± 28.63

73.57 ± 16.82

0.000

50.00 ± 23.64

72.43 ± 19.41

0.000

Vitality

41.03 ± 20.15

52.93 ± 16.77

0.035

34.14 ± 19.57

53.57 ± 17.88

0.000

46.17 ±19.34

64.41 ± 13.96

0.000

Pain

45.34 ± 25.23

67.67 ± 22.29

0.000

48.78 ± 26.81

73.57 ± 16.81

0.001

55.66 ± 29.15

72.42 ± 19.40

0.003

Figure 2. Cost-effectiveness analysis of three procedures.
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TAH, and TLH groups were $99.15 ± 4.90, $538.82 ±
193.00, and $1617.05 ± 258.44, respectively. The LNGIUS was the most cost-effective treatment choice. All costs
were significantly lower in the LNG-IUS group than in the
TAH and TLH groups (P < 0.05).
4. Discussion
HMB is a common gynecological problem that significantly
impairs the quality of life of many women. A variety
of medical and surgical therapies have been proposed
for HMB. Hysterectomy for HMB is most effective in
reducing menstrual bleeding and improving the quality of
life for most women (7), but this procedure is associated
with several complications (6). Following surgery, patients
must stay in hospital, and returning to daily and working
life takes a long time. However, the LNG-IUS is usually
inserted in outpatient gynecology clinics and does not
affect patients’ daily or working lives. Additionally, the
LNG-IUS successfully decreases menstrual blood loss in
most women (6,8). Kingman et al.’s study revealed that
the LNG-IUS can reduce menorrhagia in women with
inherited bleeding disorders (9).
HMB is a commonly encountered gynecological
problem in perimenopausal women. Menopause transition
includes a period of about 4–5 years before menopause, or
sometimes only several months, characterized by varying
degrees of somatic and psychological changes that reflect
the change in the ovarian cycle (10). Irregularity of the
menstrual cycle marks the start of the menopausal transition
in most women. Usually around their mid-forties, women’s
cycle length may initially shorten and then progressively
lengthen with the approach of the final menstrual period
(11). This irregularity seems to correspond to changes in
estrogen levels, which are predominantly the consequence
of a decline in ovarian follicle numbers (12). The treatment
for HMB in menopause transition is either hormonal
or surgical, depending on the patient’s symptoms and
diagnosis (13).
HMB is a common complaint and causes physical,
mental, and emotional problems for many women. In
the literature, the treatment of menorrhagia has been
shown to improve the quality of life (14–16). The results
of our study clearly demonstrated that all treatments (i.e.
TAH, TLH, and LNG-IUS) reduced HMB and improved

the women’s quality of life at the 6-month follow-up.
Significant improvements were observed in the general
health, physical function, physical role, emotional role,
social function, vitality, and pain parameters in all groups,
but no improvements were noted in the mental health
parameters in any group.
The follow-up time was only 6 months. TLH is less
invasive and traumatic than the abdominal approach (17),
but it is a more expensive treatment than TAH. Although
the treatment effect is enduring, most complications occur
after surgery. In our study, the LNG-IUS was much more
cost-effective than TLH and TAH at the 6-month followup, but this system may cause unexpected costs during
longer follow-ups. Therefore, long-term evaluations of
our study groups are necessary. Bleeding and spotting
disorders associated with the LNG-IUS are common
during the first few months and in most cases are resolved
after 3–6 months of use (18). In the literature, the reported
removal rate of the LNG-IUS due to bleeding problems is
low (19,20). In the present study, bleeding problems that
led to the removal of the IUS and subsequent hysterectomy
were observed in one woman. Uterine perforation is one of
the most serious complications associated with the LNGIUS, and although this complication is rare, its frequency
is likely to increase due to the increasing popularity of
the LNG-IUS (21). Laparoscopic surgical removal of an
intraperitoneal LNG-IUS is a safe and preferred method
(22). In our study, one uterine perforation was observed,
and the device was removed laparoscopically.
Cost-effectiveness analysis is an important component
of clinical trials (23,24). HMB is a major health problem for
women and requires different treatments. Hence, health
spending for HMB varies with the treatment options. It is
important to select the most cost-effective HMB treatment
approach.
In a review article, the LNG-IUS was found to be
a cost-effective option for the treatment of HMB, and
it provided benefits that were at least similar to those of
surgical procedures in terms of health-related quality-oflife outcomes (25). In our trial, the outcome measures of
the SF-36 revealed that after 6 months these treatments
were equal in terms of quality of life with the exception
of mental health, but the LNG-IUS was the most costeffective approach.
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